Vimizim® (Elosulfase Alfa) - CAM 968HB
Background
FDA-Approved Indication: Vimizim (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme replacement therapy indicated for the treatment of patients with Mucopolysaccharidosis Type IVA (MPS IVA, Morquio A Syndrome).
Policy (Criteria)
Initial Authorization Criteria
Vimizim may be considered medically necessary when all of the following criteria are met:
- Diagnosis of Mucopolysaccharidosis Type IVA (MPS IVA; Morquio A Syndrome)
- Documented clinical signs and symptoms of the disease examples include, but are not limited to:
- Kyphoscoliosis
- Genu valgum
- Pectus carinatum
- Gait disturbance
- Growth deficiency or short stature
- Skeletal dysplasia
- Joint laxity
- Cervical instability
- Abnormal pulmonary function
- Endurance limitations
- Corneal clouding
- Laboratory confirmation by one of the following:
- Documented reduced fibroblast or leukocyte GALNS enzyme activity
- Molecular genetic testing confirming pathogenic mutation(s) in the GALNS gene
- Prescribed by or in consultation with a physician experienced in the treatment of lysosomal storage disorders, inherited metabolic disorders, or MPS IVA
Authorization Duration: 12 months
Reauthorization Criteria
Vimizim may be reauthorized when all of the following criteria are met:
1. Documentation of positive clinical response or disease stabilization from baseline examples include one or more of the following:
- Improvement or stabilization in endurance testing (e.g., 6-minute walk test)
- Improvement or stabilization in pulmonary function
- Improvement in mobility or ambulation
- Improvement in activities of daily living
- Reduction in urinary keratan sulfate levels
- Stabilization of skeletal disease progression
- Improvement in quality of life measures
- Physician documentation of meaningful clinical benefit
2. Continued treatment is prescribed by or in consultation with a physician experienced in the treatment of lysosomal storage disorders, inherited metabolic disorders, or MPS IVA
Authorization Duration: 12 months
References
- Vimizim® (elosulfase alfa) Prescribing Information. BioMarin Pharmaceutical Inc. Current prescribing information.
- Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and Safety of Elosulfase Alfa in Patients with Morquio A Syndrome (MPS IVA): A Phase 3 Randomized Placebo-Controlled Study. Journal of Inherited Metabolic Disease. 2014;37(6):979-990.
- Hendriksz CJ, Giugliani R, Harmatz P, et al. Multi-Domain Impact of Elosulfase Alfa in Morquio A Syndrome. Molecular Genetics and Metabolism. 2015;114(2):178-185.
- Harmatz P, Mengel KE, Giugliani R, et al. Long-Term Follow-Up of Endurance and Safety Outcomes During Elosulfase Alfa Treatment. Molecular Genetics and Metabolism. 2015;114(2):178-185.
- GeneReviews®. Mucopolysaccharidosis Type IVA.
- National Organization for Rare Disorders (NORD). Morquio Syndrome (MPS IVA).
- American College of Medical Genetics and Genomics (ACMG). Practice guidance for diagnosis and management of lysosomal storage disorders.
- Orphanet. Mucopolysaccharidosis Type IVA (Morquio A Syndrome).
Coding Section
| Code |
Number |
Description |
| ICD-10 |
E76.210 |
Mucopolysaccharidoses IVA (MPS IVA; Morquio A Syndrome |
| HCPCS |
J1322 |
Injection, elosulfase alfa, 1 mg |
| CPT |
96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
|
|
96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure) |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |